Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.87 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711952 | 0.93 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21450459 | 0.92 | TOP1 (0.89) | TOP1SLC2A1 | |
| SCHEMBL9563446 | 0.92 | TOP1 (0.89) | TOP1SLC2A1 | |
| SCHEMBL21564110 | 0.92 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL29877390 | 0.92 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL23235265 | 0.92 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21450485 | 0.92 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL25403177 | 0.92 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL29728060 | 0.92 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL9563391 | 0.92 | TOP1 (0.87) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696331-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-119136840-A | Camptothecine derivative and ligand-medicine conjugate | 海南先声再明医药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024213128-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 山东先声生物制药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117769555-A | Camptothecin derivative, pharmaceutical composition and application thereof | 先声再明医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2019195665-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPCAM, TOP2A, SPAG5 | TOP1 4/4885SLC2A1 1660/4885 |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | TOP1 4/4885SLC2A1 3489/4885 |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | LPXN, CLSPN, SELL | TOP1 81/4885SLC2A1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.